Millendo Therapeutics, Inc. (Nasdaq: MLND), a clinical-stage biopharmaceutical company developing novel treatments for orphan endocrine diseases, today announced that senior management will present company overviews and conduct one-on-one investor meetings at the following healthcare investor conferences:

Citi’s 14th Annual Biotech Conference Date: Thursday, September 5, 2019 (one-on-one meetings only) Location: Boston, MA

Oppenheimer Fall Summit Focused on Specialty Pharma & Rare Disease Companies Date: Monday, September 23, 2019 (one-on-one meetings only) Location: New York, NY

Ladenburg Thalmann 2019 Healthcare Conference Date/Time: Tuesday, September 24, 2019 at 11:00 a.m. EDT Location: New York, NY

A live webcast of the Ladenburg Thalmann presentation will be available on the Investors & Media section of Millendo’s website at http://investors.millendo.com. A replay of the webcast will be archived on Millendo’s website for 30 days following the presentation.

About Millendo Therapeutics, Inc. Millendo Therapeutics is a late-stage biopharmaceutical company primarily focused on developing novel treatments for orphan endocrine diseases where current therapies do not exist or are insufficient. As a leading orphan endocrine company, Millendo creates distinct and transformative treatments where there is a significant unmet medical need. The company is currently advancing livoletide for the treatment of Prader-Willi syndrome, nevanimibe for the treatment of classic congenital adrenal hyperplasia and MLE-301 for the treatment of vasomotor symptoms associated with menopause. For more information, please visit www.millendo.com.

Millendo Investor Contact: Stephanie Ascher Stern Investor Relations 212-362-1200 stephanie.ascher@sternir.com Millendo Media Contact: Betsy Yates MacDougall 781-235-3094 byates@macbiocom.com

Millendo Therapeutics (NASDAQ:MLND)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more Millendo Therapeutics Charts.
Millendo Therapeutics (NASDAQ:MLND)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more Millendo Therapeutics Charts.